To be clear: Atrium Medical does not sell unbranded gray-market injections, unverified house blends, research-use products, or medication mixes marketed as cheaper Ozempic, Wegovy, Mounjaro, or Zepbound substitutes
Cagrilintide vs AOD 9604 Mechanism: Cagrilintide: Amylin receptor agonist (appetite/satiety) AOD 9604: HGH fragment (fat metabolism) Completely different Weight loss: Cagrilintide: 10-12% body weight AOD 9604: 5-8% body weight (less robust data) Cagrilintide superior Clinical evidence: Cagrilintide: Extensive Phase 2/3 trials AOD 9604: Limited clinical data Cagrilintide better studied Side effects: Cagrilintide: GI effects common AOD 9604: Minimal side effects AOD 9604 better tolerated Combination potential: Could theoretically combine (different mechanisms) No clinical data on combination Cagrilintide + semaglutide better established Verdict: Cagrilintide more powerful, better evidence
For the small number of patients whose needs may not be met by products available on the market, Hims & Hers will continue to offer compounded GLP-1s if a provider determines that they are necessary
The Food and Drug Administration approved Ozempic in 2017 for adults with Type 2 diabetes
Self-sourced injectable products or those obtained from non-medical sources carry substantial risks including contamination, incorrect concentration, inappropriate formulation, and lack of sterility
Increased needs
